Frazier Life Sciences Management’s MacroGenics MGNX Stock Holding History

Frazier Life Sciences Management’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,175,665	Closed	-$5.34M	–	47
2025 Q3	$5.34M	Hold	3,175,665	–	–	0.16%	44
2025 Q2	$3.84M	Hold	3,175,665	–	–	0.15%	47
2025 Q1	$4.03M	Hold	3,175,665	–	–	0.18%	44
2024 Q4	$10.3M	Buy	3,175,665 +164,938	+5%	+$594K	0.43%	36
2024 Q3	$9.91M	Hold	3,010,727	–	–	0.4%	39
2024 Q2	$12.8M	Buy	3,010,727 +539,023	+22%	+$5.25M	0.6%	34
2024 Q1	$36.4M	Buy	2,471,704 +70,000	+3%	+$1.06M	1.54%	20
2023 Q4	$23.1M	Buy	2,401,704 +598,500	+33%	+$4.14M	1.24%	22
2023 Q3	$8.4M	Hold	1,803,204	–	–	0.56%	36
2023 Q2	$9.65M	Buy	1,803,204 +100,000	+6%	+$617K	0.58%	32
2023 Q1	$12.2M	Buy	+1,703,204	New	+$10.3M	0.88%	27
2022 Q4	–	Sell	-701,631	Closed	-$2.43M	–	45
2022 Q3	$2.43M	Buy	+701,631	New	+$2.68M	0.19%	38

Other funds holding MGNX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Frazier Life Sciences Management's MGNX Position: Q4 2025 in Review

Frazier Life Sciences Management sold out of MacroGenics (MGNX) in Q4 2025, closing a stake of 3,175,665 shares — an estimated $5.34M sold.

Frazier Life Sciences Management first reported a position in MGNX in Q3 2022 and held it in 12 quarters. The position peaked at $36.4M in Q1 2024. 88 funds tracked by Wall St. Rank hold MGNX as of Q4 2025.

Frazier Life Sciences Management reported no remaining MacroGenics position as of Q4 2025 after selling out during the quarter.
Frazier Life Sciences Management sold 3,175,665 MacroGenics shares in Q4 2025, an estimated $5.34M.
Frazier Life Sciences Management first reported a position in MacroGenics in Q3 2022 and held it in 12 quarters.
Frazier Life Sciences Management's MacroGenics position peaked at $36.4M in Q1 2024.
88 funds tracked by Wall St. Rank held MacroGenics as of Q4 2025.

Based on Frazier Life Sciences Management's 13F filing for Q4 2025, filed 13 Feb 2026.